Fig. 2.

Percentage of patients with sPGA score of 0 (clear) or ≤ 1 (clear or almost clear) at each study visit. Observed data analysis. Error bars show the 95% confidence interval. The red arrow indicates introduction of the protocol amendment that allowed dose reductions to brodalumab 140 mg for patients weighing ≤ 100 kg. The green arrow indicates introduction of the protocol amendment that allowed dose increases to brodalumab 210 mg for patients demonstrating an insufficient response with the 140-mg dose. n number of patients who had a valid measurement value at the specified week, sPGA 0 and sPGA ≤ 1 static physician’s global assessment score of 0 and ≤ 1. ^aAt week 264, patients had been off treatment for ≥ 6 weeks